Trospium and Memory: Four Trial and Prescribing Checks

A reassuring cognitive-test result is most useful with its calendar attached. For trospium, the randomized women’s trial lasted four weeks; the prescribing precautions extend beyond that measurement.

Read the randomized trial’s population and duration

The 2017 trial¹ randomized 59 women aged 50 or older to trospium extended release or placebo. 45 completed assessment, with a mean age of 68. At four weeks, the groups did not differ significantly on the primary Hopkins Verbal Learning Test-Revised total score (P=0.29) or the other cognitive tests.¹

This measures short-term performance, not dementia diagnoses years later. The NCT01922115 registry excluded people with dementia, depression or delirium, as well as severe renal impairment. It identifies the University of North Carolina as sponsor, with the American Urogynecologic Society as collaborator. The result does not describe every older patient offered this medicine.²

Ask what happened during the first days

An earlier 2012 prospective cohort enrolled 50 women; 35 completed assessment. After starting extended-release trospium, some verbal-learning measures declined on day one or at week one, then returned to baseline by week four.³

That cohort had no placebo group. It cannot establish that trospium caused those early changes. It does show why a four-week endpoint should not replace asking about symptoms soon after treatment starts.³

Do not turn observational findings into a safety guarantee

The 2024 English study⁴, with 170,742 dementia cases and 804,385 matched controls, found no significant increase associated with cumulative trospium use. These were prescription records, not randomized treatment assignments.⁴

The 2025 Danish study⁵ reached a different result against non-use: trospium’s dementia incidence rate ratio was 1.52 (95% confidence interval 1.37–1.67). In its separate new-user comparison against mirabegron, the trospium ratio was 0.79 (0.59–1.05), without a significant difference.⁵

The comparator changes the question. Bladder symptoms, early cognitive disease and prescribing choices can differ between groups; adjustment cannot eliminate every such difference. Neither comparison proves that trospium causes dementia or prevents it.⁵ Our mirabegron and memory article examines the wider comparison between drug classes.

Keep the current label beside the study result

The May 2026 US extended-release label warns about confusion, hallucinations, dizziness and sleepiness, especially after starting treatment or increasing the dose. It advises monitoring and avoiding driving until the medicine’s effects are known. Clinicians may need to reduce or discontinue treatment if nervous-system effects occur.⁶

The label also excludes urinary retention, gastric retention and uncontrolled narrow-angle glaucoma, and does not recommend this formulation with severe renal impairment. Other antimuscarinic medicines can add to adverse effects. A reassuring trial average does not cancel these prescribing checks.⁶

Prepare a dated review

Bring the exact formulation, start date, other medicines and any new symptoms. Describe the change concretely: a missed familiar appointment, unusual daytime drowsiness or an episode of disorientation. Ask which symptoms require prompt contact and how the prescriber will weigh bladder benefit against adverse effects.

“The Next Rungs” in Laugh, Sneeze, Jump places medicines within the wider care plan and discusses cumulative anticholinergic exposure. Use that framework to agree on a review date and the bladder outcome you are tracking, alongside any cognitive concerns.